Among the most widely used therapies targeting class B1 receptors are agonists of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes (T2D) and obesity (5–8). This evidence concerns the gene GLP1R and obesity disorder.